Liquidia (NASDAQ:LQDA) CAO Dana Boyle Sells 5,892 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) CAO Dana Boyle sold 5,892 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $167,804.16. Following the transaction, the chief accounting officer owned 165,609 shares in the company, valued at $4,716,544.32. The trade was a 3.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dana Boyle also recently made the following trade(s):

• On Monday, July 27th, Dana Boyle sold 1,600 shares of Liquidia stock. The shares were sold at an average price of $87.53, for a total value of $140,048.00.

Liquidia Price Performance

Shares of LQDA stock opened at $26.81 on Wednesday. Liquidia Corporation has a twelve month low of $21.94 and a twelve month high of $93.61. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 19.57 and a beta of 0.61. The stock has a fifty day simple moving average of $63.40 and a two-hundred day simple moving average of $61.76. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%. Liquidia’s quarterly revenue was up 1842.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.49) EPS. On average, analysts predict that Liquidia Corporation will post 2.05 EPS for the current fiscal year.

Analyst Ratings Changes

LQDA has been the topic of several recent research reports. HC Wainwright dropped their target price on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, October 2nd. Piper Sandler set a $129.00 price target on shares of Liquidia in a report on Friday, July 24th. Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a report on Friday, July 24th. BTIG Research cut shares of Liquidia from a “buy” rating to a “neutral” rating in a research report on Thursday, October 1st. Finally, Bank of America upped their price target on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Liquidia currently has an average rating of “Hold” and an average target price of $83.69.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Quantinno Capital Management LP boosted its holdings in shares of Liquidia by 3.6% in the 1st quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock valued at $648,000 after buying an additional 589 shares in the last quarter. Arizona State Retirement System lifted its position in Liquidia by 5.4% in the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after acquiring an additional 900 shares during the last quarter. Swiss National Bank boosted its stake in Liquidia by 1.3% in the first quarter. Swiss National Bank now owns 120,400 shares of the company’s stock valued at $4,544,000 after acquiring an additional 1,600 shares in the last quarter. Valmark Advisers Inc. boosted its stake in Liquidia by 10.2% in the first quarter. Valmark Advisers Inc. now owns 20,546 shares of the company’s stock valued at $775,000 after acquiring an additional 1,905 shares in the last quarter. Finally, Globeflex Capital L P acquired a new position in Liquidia in the second quarter valued at $175,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).